Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Editas Medicine (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,612,352
  • Shares Outstanding, K 47,200
  • Annual Sales, $ 13,730 K
  • Annual Income, $ -120,320 K
  • 36-Month Beta 3.62
  • Price/Sales 114.78
  • Price/Cash Flow N/A
  • Price/Book 6.37

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.12 +9.77%
on 04/30/18
38.67 -11.66%
on 05/17/18
-0.30 (-0.87%)
since 04/20/18
3-Month
30.56 +11.78%
on 03/28/18
45.02 -24.12%
on 03/09/18
-0.95 (-2.71%)
since 02/22/18
52-Week
13.12 +160.37%
on 05/31/17
45.02 -24.12%
on 03/09/18
+16.71 (+95.76%)
since 05/22/17

Most Recent Stories

More News
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

Is Editas Medicine, Inc. (EDIT) Outperforming Other Medical Stocks This Year?

EDIT : 34.16 (+2.34%)
Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday,...

EDIT : 34.16 (+2.34%)
Editas Medicine Announces First Quarter 2018 Results and Update

Expanded Celgene collaboration to drive lead oncology program in solid tumors

EDIT : 34.16 (+2.34%)
CELGZ : 0.25 (unch)
Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the American Society of Gene & Cell Therapy Annual Meeting

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that 10 scientific abstracts, including three from research collaborations, have been accepted for presentation at...

EDIT : 34.16 (+2.34%)
Editas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and Results

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, May 3, 2018, at 5:00 p.m. ET to discuss a corporate update...

EDIT : 34.16 (+2.34%)
Editas Medicine Names James C. Mullen as Chairman of the Board of Directors

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of James C. Mullen as Chairman of the Board of Directors, effective immediately.

PODD : 87.49 (-1.61%)
EDIT : 34.16 (+2.34%)
New Research: Key Drivers of Growth for Editas Medicine, Magellan Health, The RMR Group, Marcus, Nordson, and USA Compression Partners, LP -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Editas Medicine, Inc. (NASDAQ:EDIT),...

NDSN : 129.25 (-7.43%)
RMR : 75.35 (-1.89%)
USAC : 18.24 (-0.05%)
MGLN : 89.45 (-0.83%)
EDIT : 34.16 (+2.34%)
MCS : 32.15 (-0.92%)
Flagship Pioneering Launches Foghorn Therapeutics With Initial Capital Commitment of $50 Million

Flagship Pioneering, a unique life science innovation enterprise, today unveiled Foghorn Therapeutics. Foghorn uses its proprietary Gene Traffic Control(TM) product platform to discover and develop drugs...

SYRS : 11.96 (unch)
MCRB : 7.98 (+6.12%)
DNLI : 20.00 (+1.42%)
EDIT : 34.16 (+2.34%)
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

BLUE : 185.65 (+2.43%)
SRPT : 89.22 (-1.77%)
EDIT : 34.16 (+2.34%)
ALGN : 297.86 (-1.52%)
NTLA : 24.58 (+0.99%)
Why Sarepta (SRPT) Jumped and We Sold

Why Sarepta (SRPT) Jumped and We Sold

SRPT : 89.22 (-1.77%)
BLUE : 185.65 (+2.43%)
EDIT : 34.16 (+2.34%)
ALGN : 297.86 (-1.52%)
NTLA : 24.58 (+0.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade EDIT with:

Business Summary

Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 35.56
1st Resistance Point 34.86
Last Price 34.16
1st Support Level 33.35
2nd Support Level 32.54

See More

52-Week High 45.02
Last Price 34.16
Fibonacci 61.8% 32.83
Fibonacci 50% 29.07
Fibonacci 38.2% 25.31
52-Week Low 13.12

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar